PORCN and esophageal adenocarcinoma: Inhibitors of porcupine O-acyltransferase (PORCN), including WNT974, have shown efficacy in preclinical models of esophageal adenocarcinoma, and their clinical evaluation in combination regimens is ongoing [49,50,51,52].